Singapore markets open in 4 hours 15 minutes

Gilead Sciences, Inc. (GIS.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
61.00-1.28 (-2.06%)
At close: 04:59PM CEST
Full screen
Previous close62.28
Open62.14
Bid60.72 x 50000
Ask60.76 x 50000
Day's range61.00 - 62.68
52-week range61.00 - 80.08
Volume365
Avg. volume498
Market cap76.548B
Beta (5Y monthly)0.20
PE ratio (TTM)14.52
EPS (TTM)4.20
Earnings date25 Apr 2024
Forward dividend & yield2.85 (4.57%)
Ex-dividend date14 Mar 2024
1y target estN/A
  • Reuters

    Gilead posts quarterly loss, revenue rises 5%

    Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales. For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but lowered its earnings outlook to include the recent charge as well as incremental expenses related to the CymaBay deal. Wall Street analysts currently project Gilead's 2024 earnings at $3.94 a share on revenue of $27.5 billion, according to LSEG data.

  • Barrons.com

    Gilead Beats Earnings Expectations After Rocky Quarter

    After a sell off that saw its shares fall nearly 20% this year, the biotech Gilead Sciences turned in first-quarter results on Thursday that were slightly better than anticipated. Sales for the quarter were $6.7 billion, beating the analyst consensus estimate as calculated by FactSet which was $6.4 billion. The company reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.

  • Business Wire

    Gilead Sciences Announces First Quarter 2024 Financial Results

    FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.